Search Results - subject:"Vioxx"

Cost benefit analysis and the FDA : measuring the costs and benefits of drug approval under the PDUFA I-II : 1998-2005

DeCanio, Samuel - In: Journal of regulatory economics 66 (2024) 2/3, pp. 174-180

Persistent link: https://www.econbiz.de/10015123272

Patent Monopolies and the Costs of Mismarketing Drugs

Baker, Dean - Center for Economic and Policy Research (CEPR) - 2015

Patent monopolies have long been used as a mechanism for financing innovation and research. The logic is that the government awards a monopoly on a product or process for a limited period of time in order to reward innovation. However, in addition to providing incentives for innovation and...

Persistent link: https://www.econbiz.de/10011265862

Drug withdrawals and the utilization of therapeutic substitutes: The case of Vioxx

Collins, J. Michael; Simon, Kosali I.; Tennyson, Sharon - In: Journal of Economic Behavior & Organization 86 (2013) C, pp. 148-168

The lack of research on how the 2004 safety-related withdrawal of the drug Vioxx affected consumer drug utilization or … withdrawal of Vioxx had both positive and negative effects for specific substitute drugs in its own class (COX-2s), and that it …

Persistent link: https://www.econbiz.de/10010688119

Drug withdrawals and the utilization of therapeutic substitutes : the case of Vioxx

Collins, J. Michael; Simon, Kosali Ilayperuma; … - In: Journal of economic behavior & organization : JEBO 86 (2013), pp. 148-168

Persistent link: https://www.econbiz.de/10009726199

Merck and Vioxx: An Examination of an Ethical Decision-Making Model

Cavusgil, Erin - In: Journal of Business Ethics 76 (2007) 4, pp. 451-461

Persistent link: https://www.econbiz.de/10005547528

The (Legal) Pains of Vioxx: Why Product Liability Can Make Products More Dangerous

Ben-Shahar, Omri - In: The Economists' Voice 3 (2007) 6, pp. 6-6

Comparing the experience of Vioxx and Celebrex leads Omri Ben-Shahar to think that stiff product liability has the …

Persistent link: https://www.econbiz.de/10005246678